Table 1

Clinical and demographic characteristics of the study groups.

Study Groups

HCV (+) HD subjects

HCV (-) HD subjects

Control subjects

N

16

24

24

Age (year)

50.3 ± 10

46.8 ± 8.5

40.4 ± 7.3

Gender (M/F)

10/6

13/11

14/10

Uric Acid (mg/dL)

5.5 ± 1.5*

5.54 ± 1.25*

4.4 ± 0.3

BUN (mg/dL)

61 ± 23*

65 ± 31*

16 ± 5.5

ALT

27 ± 13.7

22.4 ± 10.7

23.3 ± 4.8

Creatinine (mg/dL)

6.05 ± 2.4*

7.01 ± 1.5*

0.97 ± 0.15

HCV-RNA (log copies/mL)

4.9 ± 0.7

--

--

DD (Years)

4.25 ± 2.5

3.35 ± 2.7

--

TAC ( mmol Trolox eq./L)

1.27 ± 0.2

1.68 ± 0.4

2.1 ± 0.6**

TP (micromole H2O2/L)

12.9 ± 6.1**

10.9 ± 6.9**

5.2 ± 2.1

OSI (%)

1.6 ± 0.6**

1.1 ± 0.9**

0.3 ± 0.1

Data were presented as mean ± SD.

*p < 0.05 vs. controls.

**p < 0.05/3 vs. HD subjects with or without HCV infection.

***p < 0.05/3 vs. controls.

M, male; F, female; DD, dialysis duration; BUN, blood urea nitrogen; HD, hemodialysis;

HCV, hepatitis C virus; ALT, alanine aminotransferase; TAC, total antioxidant capacity; TP, total peroxide level; OSI, oxidative stress index.

Horoz et al. BMC Infectious Diseases 2006 6:114   doi:10.1186/1471-2334-6-114